Jones Trading Reiterates Buy Rating on Definium Therapeutics
Jones Trading maintained its buy rating on Definium Therapeutics, Inc. with a $74 price target, a 64.63% upside from the current price.
Key Points
- Jones Trading reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a $74 price target on June 24, 2026.
- Jones Trading's $74 price target implies 64.63% upside from Definium Therapeutics, Inc.'s ($DFTX) current $44.95 share price.
- Shares of NasdaqGS:DFTX traded near $36.18 on Wednesday, with a market cap of about $4 billion and a 52-week high of $39.16.
- Insiders, including CEO Robert Barrow, acquired shares recently, and analysts have consistently rated the stock as a strong buy.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Jones Trading reiterated its buy rating on Definium Therapeutics, Inc. (NasdaqGS: DFTX) with a price target of $74. The analyst, Justin Walsh, maintained a positive outlook on the stock, which traded at $36.18 on Wednesday.
Jones Trading vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Definium Therapeutics, Inc. Stock Up 9.7%
Shares of Definium Therapeutics, Inc. traded near $36.18 on Wednesday. The company has a market capitalization of approximately $4 billion. Despite not being profitable, with a forward P/E ratio of -23.2, Definium's stock has been volatile, with a 52-week low of $6.35 and a high of $39.16. The stock's 50-day moving average is $22.61, and its 200-day moving average is $16.28. The company boasts a strong liquidity position, with current and quick ratios around 4.6, and a debt-to-equity ratio of 14.6.
$DFTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Definium Therapeutics, Inc.
On June 22, 2026, several insiders at Definium Therapeutics, including CEO Robert Barrow and other top executives, acquired shares of the company. Barrow purchased 375,000 shares, while executives such as Chief Medical Officer Daniel Karlin and Chief Legal Officer Mark Sullivan each bought 62,500 shares. These transactions were not under any pre-planned trading agreements.
Analysts Set New Price Targets
Jones Trading maintained its buy rating on Definium Therapeutics with a $74 price target on June 24, 2026. Other firms have also shown optimism: Baird and Needham both reiterated buy ratings with targets of $57 and $50, respectively, on June 23, 2026. Leerink Partners and Oppenheimer echoed this sentiment with buy ratings and targets of $52 and $60 on June 22, 2026. The consensus among 15 analysts is a strong buy, with a mean price target of $39.87.
About Definium Therapeutics
Definium Therapeutics, Inc. is a biotechnology company based in New York, NY, specializing in developing therapies for brain health disorders. Led by CEO Robert Barrow, the company is advancing its lead product candidates, including DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism spectrum disorder. The company, formerly known as Mind Medicine (MindMed) Inc., rebranded to Definium Therapeutics in January 2026 and employs about 105 people.
Bottom Line
Definium Therapeutics continues to garner positive attention from analysts, with Jones Trading maintaining a buy rating and a $74 target. This aligns with insider confidence reflected in recent share purchases by top executives. Investors watch these developments closely, though it's important to remember that analyst ratings can be forward-looking and are not guarantees of future performance.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.